Imagine being able to treat yourself using your own blood.

​

At ErythroSIGHT (a spinout being incubated at ANU and Clear Vision Research), we are committed to developing next-generation therapeutics for the treatment of retinal- and neuro-degenerations. Using Red Blood Cell Derived Extracellular Vesicles (RBC-EVs), we are developing a safe, inexpensive and personalized blood-derived product to treat Age-related Macular Degeneration (AMD), the most common form of uncurable blindness in the western world.